EnWave Corporation (ENW:CA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings report indicates strong financial performance with significant year-over-year growth in revenue, net income, and EBITDA. The Q&A reveals a robust pipeline for large-scale machines and potential in new markets, including alternative proteins and pharmaceuticals. Despite some uncertainties, the overall outlook is optimistic with plans for expansion and profitability targets. The company's strategic focus on new markets and potential breakeven achievements suggest a positive stock price movement over the next two weeks.
Key Financial Performance
Q4 Revenue $6.2 million, up 71% year-over-year. The increase was primarily due to the sale and commissioning of 6 small-scale machines, ongoing fabrication of 2 large-scale machines, and the resale of a higher-margin large-scale machine.
Fiscal Year Revenue $13.8 million, up 69% year-over-year. This was the highest fiscal year revenue generated by EnWave's licensing royalty business as a stand-alone entity.
Net Income from Continuous Operations (Q4) $928,000, up 58% year-over-year. The increase was driven by strong revenue growth and operational performance.
Adjusted EBITDA (Q4) $1.4 million, an increase of $950,000 year-over-year. The growth was primarily driven by machine sales and the production sales mix.
Base Royalties (Q4) $418,000, up 31% year-over-year. Growth was due to increased royalty partner activity and machine capacity utilization.
Base Royalties (Fiscal Year) $1.8 million, up $228,000 year-over-year. Growth was attributed to an increased number of royalty partners and higher machine capacity utilization.
Total Royalties (Year-over-Year) Flat. This was due to a royalty partner reallocating funds from exclusivity payments to capital expenditures for acquiring large-scale machines.
Gross Margin (Q4) 41%, up from 40% in Q4 2024. The increase was due to the production mix of large and small-scale machines at various stages of production.
SG&A Expenses (Q4) $1.5 million, up 17% year-over-year. The increase was primarily related to sales personnel and increased trade show attendance.
Cash and Cash Equivalents (End of Q4) $6.4 million. The company also had a net working capital surplus of $9.7 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New REV machines: Built 2 60-kilowatt REV machines for Milne MicroDried, resold a 120-kilowatt REV machine to BranchOut Foods, and commissioned 6 10-kilowatt machines.
New licenses: Signed a new royalty-bearing commercial license with Solve Solutions of Brazil, which also purchased a 10-kilowatt machine for initial production.
Product expansion: BranchOut Foods will install a 120-kilowatt machine in Peru, bringing their total to 4 large-scale REV units and 1 10-kilowatt unit for 2026.
Geographic expansion: Solve Solutions of Brazil plans to grow manufacturing capacity for fruit, vegetable, and dairy products, with a focus on Brazil.
New market entry: Signed licenses with a U.S. snack company (production in Mexico) and Shinyway of New Zealand (cannabis drying).
Revenue growth: Q4 revenue of $6.2 million, up 71% year-over-year. Fiscal year revenue of $13.8 million, up 69% year-over-year.
Royalty growth: Base royalties reached $418,000 in Q4, the highest ever, and $1.8 million for the fiscal year, up 14% year-over-year.
Gross margin: Improved to 41% in Q4 2025 from 40% in Q4 2024.
Strategic investments: Invested $3 million from a private placement to build 2 large-scale machines and 2 additional 10-kilowatt units for inventory.
Sales strategy: Increased trade show attendance and sales personnel to drive machine sales and royalty growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Exclusivity Royalty Payments: A royalty partner decided not to pay an annual exclusivity royalty to maintain rights to produce certain tropical fruit products in a Central American country. This decision could impact total royalty revenues.
Cannabis Market Challenges: A 120-kilowatt machine was repurchased from a U.S. cannabis company, indicating potential challenges in the cannabis market that could affect future sales or royalties.
Dependence on Existing Partners: All four large-scale REV sales in fiscal 2025 were repeat orders from existing royalty partners. Heavy reliance on existing partners could pose a risk if these partners face financial or operational difficulties.
Economic and Market Uncertainty: The company acknowledges risks, uncertainties, and assumptions in its forward-looking statements, which could impact future performance.
Supply Chain and Production Risks: The manufacturing and fabrication process for large-scale machines takes approximately six months, which could delay order fulfillment and impact revenue if supply chain disruptions occur.
Geographic Concentration Risk: A partner redeployed capital to a different strategic area, which may indicate potential risks associated with geographic concentration or market shifts.
Increased SG&A Expenses: SG&A expenses, including R&D, increased by 17% year-over-year, primarily due to sales personnel and trade show attendance. This could pressure margins if revenue growth does not keep pace.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Royalty Growth: Base royalties are expected to grow due to increased capacity utilization by royalty partners and the commissioning of new large-scale machines in fiscal 2026. Four large-scale machines sold in fiscal 2025 are expected to begin commercial production and generate royalties in fiscal 2026.
Machine Sales: The company anticipates superior machine sale performance in fiscal 2026, with at least half of potential orders expected to come from existing royalty partners. Two large-scale machines and two additional 10-kilowatt units are being built to meet prospective demand.
BranchOut Foods: BranchOut Foods is expected to grow its production needs in 2026, with a bullish outlook for sales growth and subsequent royalty payments to EnWave.
Solve Solutions of Brazil: Solve Solutions plans to grow manufacturing capacity through 2026 for fruit, vegetable, and dairy product production. To maintain product exclusivity in Brazil, they are required to purchase a large-scale REV machine by March 31, 2026.
U.S. Snack Company: A U.S. snack company is expected to acquire additional REV units in fiscal 2026 to expand production.
Sales and Marketing: The company plans to attend three additional trade shows in Q2 2026 to enhance sales and marketing efforts.
Inventory and Order Fulfillment: The company is manufacturing two large-scale machines and two additional 10-kilowatt units to ensure faster order fulfillment and support prospective future machine sales.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are there any product areas of strength that you're seeing in your machine order pipeline?
A:The company has been gaining more pipeline in fruit and vegetable production beyond North and South America, with new opportunities in Europe and Southeast Asia. They are also exploring projects with alternative proteins, such as black soldier fly larva drying solutions, and engaging with industrial companies, though details are not yet disclosed.
Q:What are you seeing in terms of your overall pipeline for large-scale machines compared to last year?
A:The pipeline is better than last year. The company confirmed 4 large-scale machines in fiscal '25 and aims for 6 to 8 machines in fiscal '26, though timing depends on decisions from partners and new business opportunities.
Q:Are you seeing opportunities to ramp up tolling activities again, and how does tolling fit into your overall strategy?
A:The REVworx toll manufacturing facility is intended as a launch pad for companies to justify their business case and invest in equipment. The company does not plan for tolling to exceed $1.5 million to $2 million in annual revenue. Currently, about a dozen companies are evaluating new products through this facility, with hopes of converting them into royalty partners.
Q:Why is there a huge increase in the long-term portion of lease liabilities in the balance sheet?
A:The increase is due to a new manufacturing lease closer to the head office, which consolidates manufacturing, R&D, and REVworx facilities. There is no change in manufacturing capacity.
Q:Do you still see potential in the cannabis market?
A:Yes, there is potential in the cannabis market. While the focus remains on the food industry, the company is engaged with licensed producers in Canada, Europe, and Australasia. A Canadian company using a large-scale machine may expand production capacity using REV in fiscal '26.
Q:Can you comment on efforts in the pharmaceutical industry with your partner in Germany?
A:The partnership with GEA Lyophil involves a pilot-scale GMP vacuum microwave dryer for product development with leading pharmaceutical companies. Progress depends on finding a company or consortium to commit to developing a drug using this technology. Additionally, Bio Technique in the U.S. has conducted paid trials with encouraging results, but significant investment is needed for broader adoption.
Q:When do you expect to become profitable?
A:The company aims for cash flow breakeven with 4 large-scale machine sales per year and historical royalty rates. Improving on fiscal '25's performance of 4 machines would bring them closer to profitability.
Q:What would royalties be next year based on existing machine sales and usage volumes?
A:A conservative estimate for fiscal '26 royalties is $2.3 million, based on increased capacity utilization of existing machines and the timing of new large-scale purchase orders.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the industrial projects they are engaged in, citing confidentiality. Additionally, while they expressed optimism about opportunities in the pharmaceutical sector, they did not provide concrete timelines or commitments for commercialization.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BranchOut Foods
Charleton
FoodTech
MicroDried
REV machine
Solve
base royalty
capacity utilization
credit facility
dairy
date
exclusivity
inventory
kilowatt REV
kilowatt machine
kilowatt unit
license
machine kilowatt
machine sale
machinery
order
payment
period increase
proceeds
revenue
royalty partner
sale marketing
scale REV
scale machine
snack
trade show
unit production
WLK Transcript
Westlake Corporation (WLK) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call reveals a 10% revenue decline and a 15% drop in net income, primarily due to pricing pressures and increased raw material costs. Additionally, EBITDA and operating cash flow both decreased, indicating financial strain. The absence of positive strategic updates or shareholder return plans further dampens sentiment. While there are no explicit risks mentioned, the financial performance suggests challenges. Given these factors, a negative sentiment is appropriate, predicting a stock price movement between -2% to -8% over the next two weeks.
Westlake Corporation (WLK) Presents at JPMorgan Industrials Conference 2026 Transcript
Neutral3-20
Westlake Corporation (WLK) Q4 2025 Earnings Call Transcript
Unknown2-24
The earnings call revealed mixed signals: strong financial metrics with a focus on cost savings and strategic acquisitions, but tempered by weak guidance and cautious market outlooks. The Q&A highlighted uncertainties, such as vague responses on free cash flow and tariff impacts, which prevent a strong positive sentiment. The lack of specific guidance and cautious tone, alongside structural cost savings and strategic investments, suggest a neutral short-term stock price movement.
EnWave Corporation (ENW:CA) Q4 2025 Earnings Call Transcript
Positive12-15
The earnings report indicates strong financial performance with significant year-over-year growth in revenue, net income, and EBITDA. The Q&A reveals a robust pipeline for large-scale machines and potential in new markets, including alternative proteins and pharmaceuticals. Despite some uncertainties, the overall outlook is optimistic with plans for expansion and profitability targets. The company's strategic focus on new markets and potential breakeven achievements suggest a positive stock price movement over the next two weeks.
WLK Slides
WLK Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
